Physicians Lament Over Reliance on Relative Value Units: Survey medscape.com/viewarticle/ph… This is concerning

Are DOACs a safe alternative to VKAs for antiphospholipid syndrome? Recent findings suggest caution. 🩺 pubmed.ncbi.nlm.nih.gov/38968567 Giuseppe Biondi-Zoccai #Anticoagulation #APS #DOACs #Thrombosis #CardiologyResearch

Happy to see our work on novel therapeutic strategies targeting #thromboinflammation in venous thromboembolism featured in JACC Journals 🧯🔥🩸 Marc Carrier AntonioAbbate Marcello Di Nisio Yogen Kanthi #cvCoag #CardioTwitter #VTE

Must read … by the one-and-only Nicola Potere UVA CVRC UVA Cardio VCU Health Pauley Heart Center

Dual Pathway Inhibition reduces cardiovascular risk—new study highlights benefits and safety in stable CVD patients. 💊❤️ pubmed.ncbi.nlm.nih.gov/38922582 Francisco José Romeo 🇦🇷🇺🇸 AntonioAbbate Giuseppe Biondi-Zoccai UMCardiology Fellows @umiamihealth Miller Medicine #CardiovascularHealth #Atherosclerosis #Heart

news.med.virginia.edu/research/jonat… Jonathan Lindner, MD, and Brent French, PhD, Awarded $2.9 Million to Study Ultrasound Cavitation to Enhance AAV Gene Therapy in the Heart UVA Cardio Christopher Kramer MD

Depressive Symptom Severity Linked With Subjective Functional Ability in HFrEF thecardiologyadvisor.com/news/depressiv…

Congratulations

Looking forward to this

#ESC2024

lunch with my IMedCV Hospital Italiano family at #ESC2024 Carla Agatiello Giuliana Corna Juan Valle Raleigh, MD 🇦🇷 Ignacio Seropian MD

The one and only Michele Golino talking about recurrent pericarditis & Rilonacept in the #ESCCongress Congrats !!

Inflammatory status tells it all! A single combined measure of high-sensitivity CRP, LDL cholesterol, and lipoprotein(a) levels among 27,939 initially healthy U.S. women was predictive of incident cardiovascular events during a 30-year period. These data support efforts to

Excellent points - I fully agree - good information - no apparent harm - good basis for identifying optimal anti-inflammatory therapies in AMI

Again, you are right - there is likely a benefit of COX-2 inhibition- and the concerns for toxicity may be possibly overrated and the risk may be managed by concomitant therapies used in AMI

Thanks to all those who came to chat with me. Let me know if you have questions re Journal of Cardiovascular Pharmacology

Congrats to Allan L. Klein team for the important work. Read the editorial "Risk Stratification of Recurrent Pericarditis: Hype or Hope? " in JACC Journals jacc.org/doi/full/10.10… Always a pleasure to work with Massimo Imazio

whatispericarditis.com Nice patient-centered website with info on #pericarditis Brittany Weber Dr. Michael Garshick Allan L. Klein Massimo Imazio Paul Cremer MD UVA Cardio UVA CVRC

Heart condition POTS may be linked to COVID youtu.be/VwXKAZNUKgY?si… via YouTube With the resurgence of COVID-19, be mindful of cardiovascular complications that may occur even after mild illnesses, and preferentially affecting young women.